Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.

Zhang Y, Farenholtz KE, Yang Y, Guessous F, Dipierro CG, Calvert VS, Deng J, Schiff D, Xin W, Lee JK, Purow B, Christensen J, Petricoin E, Abounader R.

Clin Cancer Res. 2013 Mar 15;19(6):1433-44. doi: 10.1158/1078-0432.CCR-12-2832.

2.

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.

Mol Cancer Ther. 2009 Jul;8(7):1751-60. doi: 10.1158/1535-7163.MCT-09-0188.

3.

Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.

Johnson J, Ascierto ML, Mittal S, Newsome D, Kang L, Briggs M, Tanner K, Marincola FM, Berens ME, Vande Woude GF, Xie Q.

J Transl Med. 2015 Sep 17;13:306. doi: 10.1186/s12967-015-0667-x.

4.

A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.

Awazu Y, Nakamura K, Mizutani A, Kakoi Y, Iwata H, Yamasaki S, Miyamoto N, Imamura S, Miki H, Hori A.

Mol Cancer Ther. 2013 Jun;12(6):913-24. doi: 10.1158/1535-7163.MCT-12-1011.

5.

The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.

Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG.

Neoplasia. 2009 May;11(5):448-58, 2 p following 458.

6.

Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.

Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, Burger P, Laterra J.

J Natl Cancer Inst. 1999 Sep 15;91(18):1548-56. Erratum in: J Natl Cancer Inst 2000 Jan 5;92(1):78.

7.

The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.

Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, Kuchner EB, Eberhart C, Laterra J, Abounader R.

Cancer Res. 2005 Oct 15;65(20):9355-62.

8.

An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Guessous F, Zhang Y, diPierro C, Marcinkiewicz L, Sarkaria J, Schiff D, Buchanan S, Abounader R.

Anticancer Agents Med Chem. 2010 Jan;10(1):28-35.

9.

Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.

Lal B, Xia S, Abounader R, Laterra J.

Clin Cancer Res. 2005 Jun 15;11(12):4479-86.

10.

Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.

Garnett J, Chumbalkar V, Vaillant B, Gururaj AE, Hill KS, Latha K, Yao J, Priebe W, Colman H, Elferink LA, Bogler O.

Neoplasia. 2013 Jan;15(1):73-84.

11.

PTEN reconstitution alters glioma responses to c-Met pathway inhibition.

Goodwin CR, Lal B, Ho S, Woodard CL, Zhou X, Taeger A, Xia S, Laterra J.

Anticancer Drugs. 2011 Oct;22(9):905-12. doi: 10.1097/CAD.0b013e3283484750.

12.

Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.

Wu W, Bi C, Credille KM, Manro JR, Peek VL, Donoho GP, Yan L, Wijsman JA, Yan SB, Walgren RA.

Clin Cancer Res. 2013 Oct 15;19(20):5699-710. doi: 10.1158/1078-0432.CCR-13-1758.

13.
14.

Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.

Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK.

Clin Cancer Res. 2013 Apr 1;19(7):1773-83. doi: 10.1158/1078-0432.CCR-12-1281.

15.

Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.

Li Y, Guessous F, DiPierro C, Zhang Y, Mudrick T, Fuller L, Johnson E, Marcinkiewicz L, Engelhardt M, Kefas B, Schiff D, Kim J, Abounader R.

Mol Cancer Ther. 2009 Feb;8(2):376-85. doi: 10.1158/1535-7163.MCT-08-0627.

16.

Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways.

Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM, Laterra J.

Cancer Res. 2000 Aug 1;60(15):4277-83.

17.

Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.

Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.

Mol Cancer Ther. 2015 Feb;14(2):533-41. doi: 10.1158/1535-7163.MCT-14-0456.

18.

In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.

Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, Laterra J.

FASEB J. 2002 Jan;16(1):108-10.

19.

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.

Crosswell HE, Dasgupta A, Alvarado CS, Watt T, Christensen JG, De P, Durden DL, Findley HW.

BMC Cancer. 2009 Nov 25;9:411. doi: 10.1186/1471-2407-9-411.

20.

Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.

Nakagawa T, Matsushima T, Kawano S, Nakazawa Y, Kato Y, Adachi Y, Abe T, Semba T, Yokoi A, Matsui J, Tsuruoka A, Funahashi Y.

Cancer Sci. 2014 Jun;105(6):723-30. doi: 10.1111/cas.12409.

Items per page

Supplemental Content

Support Center